Arie Belldegrun, Director at Allogene Therapeutics, Inc. (ALLO), bought 3,793,102 shares at $2.90 ($11.0M) on 2024-05-16, disclosed to the SEC on 2024-05-20.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $2.90 | 344,828 | $1.0M | 9.1% |
| 2 | $2.90 | 1,724,137 | $5.0M | 45.5% |
| 3 | $2.90 | 1,724,137 | $5.0M | 45.5% |
| Total | $2.90 avg | 3,793,102 | $11.0M | 100% |
| Filing → |
| ALLO | BUY | 2019-02-13 | $3.5M | — | Filing → |
| KITE | SELL | 2017-09-27 | $9.5M | — | Filing → |
| KITE | BUY | 2017-05-09 | $1.2M | — | Filing → |